Open AccessFeasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Ongoing Phase III Sierra Trial Experience at 6 Study Sites
Author(s) -
Rajneesh Nath,
Bae P. Chu,
Lingyun Chen,
Amir Sadeghi,
Todd Senglaub,
L. R. Kaiser,
Christopher Saganich,
Michael Zgaljardic,
Frank Rutar,
Sean Harling,
Qing Liang,
Parameswaran Hari,
Koen van Besien,
Zaid AlKadhimi,
Michael W. Schuster,
Vijay Reddy,
Mark S. Berger,
Sandy Konerth,
Misty Liverett,
Boglarka Gyurkocza
Publication year - 2020
Publication title -
biology of blood and marrow transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.301
H-Index - 120
eISSN - 1523-6536
pISSN - 1083-8791
DOI - 10.1016/j.bbmt.2019.12.687
Subject(s) - medicine , clinical trial , surgery , nuclear medicine
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom